Premium lens technology closes the gap between cataract surgery and natural vision

Overview

For a decade, patients choosing premium lenses during cataract surgery have faced a trade-off: better vision range, but dimmer, lower-contrast sight—especially in low light. On March 12, 2026, the FDA approved Johnson & Johnson's TECNIS PureSee, the first extended depth of focus lens cleared in the U.S. without a contrast sensitivity warning.

In clinical trials, 97% of patients reported no bothersome visual disturbances like halos or glare. Roughly four million Americans have cataract surgery yearly, and premium lenses—which reduce dependence on glasses—have surged from 33% of global implantations in 2021 to 46% in 2024. This lens could reshape the market, reaching $8 billion by 2035.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

97%

Patients with no bothersome visual disturbances

In clinical trials, nearly all PureSee recipients reported no very bothersome halos, glare, or starbursts.

~4M

Annual U.S. cataract surgeries

Cataracts are the leading cause of vision loss globally, and the United States performs about four million procedures per year.

~500K

Eyes treated with PureSee worldwide

Nearly half a million eyes have already received the lens internationally since its 2024 launch outside the U.S.

46%

Global premium IOL adoption rate (2024)

Premium lenses now account for nearly half of all new implantations, up from 33% in 2021.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Timeline Five events from this story — drag them oldest to newest. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Tim Schmid

Leading J&J's medical device growth strategy, including vision

Organizations Involved

Johnson & Johnson Vision

Medical Device Manufacturer

Expanding premium IOL portfolio with three complementary lens platforms

Johnson & Johnson Vision manufactures the TECNIS platform of intraocular lenses and is one of the three dominant players in the global IOL market.

U.S. Food and Drug Administration

Federal agency

Approved PureSee without contrast sensitivity warning based on clinical data

The FDA regulates medical devices including intraocular lenses, reviewing clinical trial data to determine safety and labeling requirements before allowing U.S. sale.

Alcon

Medical Device Manufacturer

Leading IOL competitor with Vivity EDOF and PanOptix trifocal platforms

Alcon is the world's largest eye care device company and J&J Vision's primary competitor in the premium intraocular lens market.

Timeline

July 2016 March 2026

9 events Latest: March 12th, 2026 · 4 months ago

Tap a bar to jump to that date

March 2026
FDA approves first EDOF lens without contrast sensitivity warning
Latest Regulatory

The FDA cleared Johnson & Johnson's TECNIS PureSee for the U.S. market, the first extended depth of focus intraocular lens approved without a warning for loss of contrast sensitivity. Nearly 500,000 eyes had already received the lens internationally. U.S. availability is expected later in 2026.
March 12th, 2026
October 2024
J&J completes premium IOL trifecta with Odyssey approval
Regulatory

The FDA approved the TECNIS Odyssey, the first full visual range lens meeting new international standards. It reached 100,000 U.S. eyes within its first year, giving J&J a three-tier IOL lineup ahead of PureSee's U.S. entry.
October 1st, 2024
February 2024
TECNIS PureSee launches internationally
Product Launch

Johnson & Johnson began selling the TECNIS PureSee in Europe, the Middle East, and Africa, following earlier launches in South Korea and New Zealand. The purely refractive lens design began accumulating real-world data outside clinical trials.
February 15th, 2024
July 2022
Small-aperture IOL adds another approach to extended focus
Regulatory

The FDA approved the IC-8 Apthera from AcuFocus, a lens using a pinhole-like aperture to extend depth of focus. It offered a different optical principle but reduced light reaching the retina, limiting low-light performance.
July 22nd, 2022
February 2021
J&J launches enhanced monofocal as mid-tier option
Product Launch

The FDA approved the TECNIS Eyhance, a monofocal lens with a modified surface that slightly extended depth of focus. It was the first monofocal design innovation in 20 years, offering 30% better image contrast in low light than competitors.
February 2nd, 2021
February 2020
Alcon introduces non-diffractive EDOF approach
Regulatory

The FDA approved Alcon's Vivity, a non-diffractive extended depth of focus lens that stretched light rather than splitting it. Despite the new design, FDA labeling still warned of significant contrast sensitivity loss.
February 1st, 2020
August 2019
First trifocal lens approved in the United States
Regulatory

The FDA approved Alcon's AcrySof IQ PanOptix, the first trifocal intraocular lens available in the U.S. It provided near, intermediate, and distance vision but used light-splitting optics that reduced contrast sensitivity.
August 27th, 2019
February 2017
Johnson & Johnson acquires Abbott Medical Optics
Business

Johnson & Johnson completed its $4.3 billion acquisition of Abbott Medical Optics, gaining the TECNIS IOL platform and entering the premium lens market. The division was renamed Johnson & Johnson Vision.
February 27th, 2017
July 2016
First extended depth of focus lens reaches U.S. market
Regulatory

The FDA approved Abbott Medical Optics' TECNIS Symfony, the first intraocular lens in a new category called extended depth of focus. It provided better intermediate vision than standard lenses but carried warnings about contrast sensitivity loss.
July 15th, 2016

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 1949

The first intraocular lens implant (1949)

British ophthalmologist Harold Ridley implanted the first intraocular lens at St. Thomas' Hospital in London, after noticing that Royal Air Force pilots who got acrylic shards from shattered canopies lodged in their eyes did not reject the material. The medical establishment initially rejected the idea, and it took decades for IOL implantation to become standard practice.

Then

Ridley faced professional ostracism and skepticism for years. Early lenses had high complication rates.

Now

Intraocular lens implantation became the standard of care for cataract surgery worldwide by the 1980s. The procedure is now the most commonly performed surgery in medicine.

Why this matters now

The PureSee approval is the latest step in a 77-year evolution from Ridley's improvised acrylic disc to precision-engineered refractive optics. Each generation has moved closer to replicating the natural lens's full capabilities.

1999-2005

LASIK approval transforms vision correction (1999)

The FDA approved the first LASIK lasers in 1999, enabling refractive surgery that reshaped the cornea to correct nearsightedness, farsightedness, and astigmatism. Early LASIK patients frequently reported halos, glare, and reduced contrast sensitivity—the same complaints that plagued early premium IOLs.

Then

LASIK adoption surged despite visual side effects, peaking at about 1.4 million procedures per year in the United States by 2007.

Now

Iterative improvements in laser technology and patient screening reduced side effects dramatically. Wavefront-guided LASIK now produces fewer visual disturbances than earlier generations, and the procedure remains widely popular.

Why this matters now

LASIK's trajectory illustrates how early-generation vision correction technologies carry visual side effects that improve with subsequent designs. The PureSee's elimination of the contrast sensitivity warning mirrors the refinement arc that LASIK followed over two decades, compressed into a single product generation.

August 2019

AcrySof IQ PanOptix trifocal IOL approval (2019)

Alcon's PanOptix became the first trifocal intraocular lens approved in the United States, offering near, intermediate, and distance vision in a single lens. The light-splitting diffractive design provided the widest range of clear vision available at the time but came with the familiar trade-off: reduced contrast sensitivity and increased visual disturbances, particularly halos at night.

Then

PanOptix rapidly gained market share, with Alcon reporting that over 99% of patients said they would choose the same lens again despite the side effects.

Now

The approval helped establish patient demand for glasses-free vision after cataract surgery and pushed competitors to develop lenses with fewer optical compromises.

Why this matters now

PanOptix demonstrated that patients were willing to accept some visual trade-offs for freedom from glasses. PureSee's clinical data suggests a new generation may no longer require that trade-off, potentially resetting patient expectations for what premium lenses should deliver.